List view / Grid view
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
A newly developed peptide, WRPRFa, is giving scientists a clearer view of how the acid-sensing ion channel (ASIC3) drives pain signalling.
The articles in this in-depth focus explain how informatics aids in the development of genomic research and outline the next steps for AI to progress in pharma.
This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an ADC and the potential of antibodies as a targeted cancer therapeutic.
Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic and pharmacogenomic testing can improve healthcare options.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
Drug Target Review explores the findings of a recent review of molecular, cellular, multi-cellular and tissue engineering and modelling technologies for drug design.
Pre-clinical studies demonstrate that inhibiting the ’epichaperome’ can restore neural networks to normal levels. Dr Barbara Wallner at Samus Therapeutics explains how targeting the epichaperome could work as a potential treatment for Alzheimer’s and other neurodegenerative diseases.
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
Drug Target Review explores five of the latest research developments in the field of spinal cord injury (SCI) repair.
Drug Target Review rounds up the latest updates on research into coronavirus treatments, focusing on virtual screening to find therapies for COVID-19.
A new microfluidic technology has been developed by researchers, which utilises magnetic ferrobots to automate chemical analyses and assays.
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
Neuropathologic similarities between dolphins and humans suggest that the former could act as an effective model for the study of diseases such as Alzheimer’s. Professor Giovanni Di Guardo explains why dolphins could provide researchers with a new window into neurodegenerative conditons.
